个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

The Reporting Completeness of Patient-Reported Outcome in Randomized Controlled Trials of Non-Small Cell Lung Cancer Could Be Improved: A Systematic Review

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
He Wenbo[1] * ; Jing Fangyuan[2] ; Gao Yinyan[3] ; Yi Hang[4] ; Li Meixuan[5,6,7] ; You Jiuhong[8] ; Shen Yanjiao[1] ; Wu Yi[9] ; Kang Pan[10] ; Yu Zhiruo[1] ; Wang Xinyi[1] ; Luo Yunmei[11] ; Li Zhengchi[12] ; Du Liang[1,11,12] ;
机构： [1]Innovation Institute for Integration of Medicine and Engineering, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China. [2]Department of Rehabilitation Medicine, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, China. [3]Department of Epidemiology and Biostatistics, Xiangya School of Public Health, Central South University, Changsha, China. [4]Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [5]Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China. [6]Health Technology Assessment Center, Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China. [7]Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China. [8]Department of Psychological Medicine, Center for Healthy Brain Ageing, Institute of Pychiatry, Pychology, and Nuroscience, King's College London, London, UK. [9]Department of Medical Quality Control, Baoji Hospital Affiliated to Xi'an Medical College, Baoji, China. [10]School of Public Health, Lanzhou University, Lanzhou, China. [11]West China Medical Publishers, West China Hospital, Sichuan University, Chengdu, China. [12]Center for education of Medical Humanities, West China Hospital, Sichuan University, Chengdu, China.
出处：
DOI： 10.1002/pon.70152
ISSN：

关键词： cancer influencing factor methodological quality non‐small cell lung cancer oncology patient‐reported outcomes quality of life randomized controlled trials reporting quality systematic review

摘要：
Non-small cell lung cancer (NSCLC) remains a highly symptomatic with a rapidly increasing incidence. The treatment options are for most patients limited to adjuvant immunotherapy and best supportive care. Therefore, patient-reported outcomes (PROs) are increasingly becoming an essential component in evaluating healthcare quality from the patient's perspective.We aimed to assess differences in the use of PROs measurement tools and their reporting quality in NSCLC randomized controlled trials (RCTs).We searched for reports of PROs in NSCLC RCT studies in PubMed, Embase, Web of Science, and Scopus before June 6, 2024. The quality of PRO reporting was assessed using criteria recommended by the International Society for Quality-of-Life Research. Multivariate linear regression was performed to examine the relationship between report quality and influencing factors.A total of 252 RCTs were included in the analysis, with 23% of these studies reporting PROs as primary endpoints. Overall, studies with PROs as primary endpoints demonstrated higher adherence to the reporting checklist (76%). The results of multivariate linear regression indicated a significant improvement in PRO reporting quality over time (β = 5.35, 95% CI [1.05, 9.64], p < 0.05). However, substantial shortcomings were identified in PRO reporting, including incomplete reporting of missing data and a lack of details on PRO data management modes (e.g., telephone, computer, etc.).The deficiencies observed in PRO reporting underscore the need for improved design and implementation of PRO endpoints in future NSCLC trials. Enhancing the quality of PRO reporting could improve the relevance and applicability of research findings to clinical practice.© 2025 John Wiley & Sons Ltd.

基金：
National Natural Science Foundation of China (Grant No. 82405611) and Sichuan University Interdisciplinary Innovation Fund.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 2 区 医学
小类 | 2 区 社会科学：生物医学 3 区 肿瘤学 3 区 心理学 3 区 心理学：综合
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 社会科学：生物医学 3 区 肿瘤学 3 区 心理学 3 区 心理学：综合
第一作者：
第一作者机构： [1]Innovation Institute for Integration of Medicine and Engineering, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China.
通讯作者：
通讯机构： [1]Innovation Institute for Integration of Medicine and Engineering, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China. [11]West China Medical Publishers, West China Hospital, Sichuan University, Chengdu, China. [12]Center for education of Medical Humanities, West China Hospital, Sichuan University, Chengdu, China.
推荐引用方式(GB/T 7714)：
He Wenbo,Jing Fangyuan,Gao Yinyan,et al.The Reporting Completeness of Patient-Reported Outcome in Randomized Controlled Trials of Non-Small Cell Lung Cancer Could Be Improved: A Systematic Review[J].Psycho-Oncology.2025,34(4):e70152.doi:10.1002/pon.70152.
APA：
He Wenbo,Jing Fangyuan,Gao Yinyan,Yi Hang,Li Meixuan...&Du Liang.(2025).The Reporting Completeness of Patient-Reported Outcome in Randomized Controlled Trials of Non-Small Cell Lung Cancer Could Be Improved: A Systematic Review.Psycho-Oncology,34,(4)
MLA：
He Wenbo,et al."The Reporting Completeness of Patient-Reported Outcome in Randomized Controlled Trials of Non-Small Cell Lung Cancer Could Be Improved: A Systematic Review".Psycho-Oncology 34..4(2025):e70152

相关文献

[1]Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer [2]The reporting quality and methodological quality of dynamic prediction models for cancer prognosis [3]Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer. [4]Planning and reporting of quality-of-life outcomes in cancer trials. [5]Reporting Quality of Randomized, Controlled Trials Evaluating Combined Chemoradiotherapy in Nasopharyngeal Carcinoma. [6]Early Postoperative Patient-Reported Outcomes After Thoracoscopic Segmentectomy Versus Lobectomy for Small-Sized Peripheral Non-small-cell Lung Cancer [7]Comparison of early patient-reported outcomes between uniportal thoracoscopic segmentectomy and wedge resection for peripheral small-sized non-small-cell lung cancer [8]Early PROs after Thoracoscopic Segmentectomy versus Wedge Resection for Small-sized Peripheral NSCLC [9]Patient-Reported Outcomes in Chinese Patients with Locally Advanced or Recurrent Colorectal Cancer After Pelvic Exenteration [10]利妥昔单抗治疗B细胞非霍奇金淋巴瘤系统评价

资源点击量：57690 今日访问量：1 总访问量：4767 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号